No image published for this recall
An official FDA notice concerns Apotex - safety alert. An official FDA notice concerns Apotex. The notice reports a potential product safety risk. Follow the official notice for consumer instructions. Published 2017-02-15. Lots: MJ7746. Recall numbers: D-0471-2017. Check the official notice for the complete list. Published 2017-02-15.
What to do now
The source does not provide specific consumer instructions. Follow the official FDA notice for next steps.
Units affected
67,946
Recall number
D-0471-2017
Official notice
2017-02-15
The hazard
The hazard
An official FDA notice concerns Apotex. The notice reports a potential product safety risk. Follow the official notice for consumer instructions. Published 2017-02-15. Lots: MJ7746. Recall numbers: D-0471-2017. Check the official notice for the complete list.
How to check if you're affected
How to check if you're affected
Compare the product name and identifiers below with the item you own. Follow the official notice if they match.
Lots
Event Ids
Recall Numbers
Checked manually this time?
The app alerts you when a new official recall is published — no searching, no checking back.
Turn on recall alertsWhere it was sold
Where it was sold
The source does not list specific retailers. See the official notice for where affected products were sold.
Location 1
Affected area 1
Affected area 2
Company & contacts
Company & contacts
Brand: Apotex. Contact: Apotex Inc..
Source & status
Source & status
Recall details
Recall details
Recall number
Event id
Units affected
Status
Source tier
Documents, notices & source
See the official notice and source documents for full details.
View full official noticeRelated recalls
Apo-fluoxetine: the impurities are out of specification and out of trend
10 Apr 2026Apo-brimonidine-timop: the weight is out of specification in the affected lot.
Apo-candesartan: affected lots were manufactured using an active ingredient that was out of specification for dissolution
Apo-travoprost-timop pq: missing the documented justification for the results obtained.
Extra strength ibuprofen liquid gel capsules: presence of cloudy capsules in affected lots
a product listed in the official notice - safety alert
a product listed in the official notice - safety alert
a product listed in the official notice - safety alert
a product listed in the official notice - safety alert
a product listed in the official notice - safety alert
a product listed in the official notice - safety alert
a product listed in the official notice - safety alert
Apo-fluoxetine: the impurities are out of specification and out of trend
Apo-brimonidine-timop: the weight is out of specification in the affected lot.
Apo-candesartan: affected lots were manufactured using an active ingredient that was out of specification for dissolution
Apo-travoprost-timop pq: missing the documented justification for the results obtained.
Extra strength ibuprofen liquid gel capsules: presence of cloudy capsules in affected lots
Weekly recall digest
Get next week's recalls before you need them.
One email every Monday — official-source recalls for your country, and nothing else. Unsubscribe from any email.
The digest is the slow lane — one email a week. For instant, severity-gated alerts the moment a notice is published, get the app.
This recall was published 15 Feb 2017. The next one won't wait for you to search.
RecallScope watches official sources for the brands and VINs you follow, and alerts you the moment a new notice is published.
